Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Abstract

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

1 - 30 . (canceled) 
     
     
         31 . A method for treating or ameliorating Alagille syndrome in a pediatric subject comprising administering to the pediatric subject an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI), the ASBTI is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, or prodrug thereof. 
     
     
         32 . A method for treating or ameliorating pruritis in a pediatric subject suffering from Alagille syndrome comprising administering to the pediatric subject an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI), the ASBTI is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, or prodrug thereof. 
     
     
         33 . A method for treating or ameliorating Alagille syndrome in a pediatric subject comprising administering to the pediatric subject a pharmaceutical composition comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI), the ASBTI is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt solvate, or prodrug thereof. 
     
     
         34 . The method of  claim 31 , wherein the method comprises reducing xanthoma, serum lipoprotein X, liver enzymes, bilirubin, intraenterocyte bile acids/salts, or necrosis and/or damage to hepatocellular architecture. 
     
     
         35 . The method of  claim 33 , wherein the composition is a pediatric dosage form. 
     
     
         36 . The method of  claim 35 , wherein the pediatric dosage form is selected from a solution, syrup, suspension, elixir, powder for reconstitution as suspension or solution, dispersible/effervescent tablet, chewable tablet, gummy candy, lollipop, freezer pops, troches, oral thin strips, orally disintegrating tablet, sachet, soft gelatin capsule, and sprinkle oral powder or granules. 
     
     
         37 . The method of  claim 31 , wherein the ASBTI is administered in an amount between about 10 μg/kg/day and about 300 μg/kg/day. 
     
     
         38 . The method of  claim 31 , wherein the ASBTI is administered in an amount between about 14 μg/kg/day to about 280 μg/kg/day. 
     
     
         39 . The method of  claim 31 , wherein the ASBTI is administered in an amount between about 14 μg/kg/day to about 140 μg/kg/day. 
     
     
         40 . The method of  claim 35 , wherein the pediatric dosage form comprises between 0.1 to 20 mg of the ASBTI. 
     
     
         41 . The method of  claim 31 , wherein the Alagille syndrome is characterized by one or more symptoms selected from jaundice, pruritis, cirrhosis, hypercholemia, neonatal respiratory distress syndrome, lung pneumonia, increased serum concentration of bile acids, increased hepatic concentration of bile acids, increased serum concentration of bilirubin, hepatocellular injury, liver scarring, liver failure, hepatomegaly, xanthomas, malabsorption, splenomegaly, diarrhea, pancreatitis, hepatocellular necrosis, giant cell formation, hepatocellular carcinoma, gastrointestinal bleeding, portal hypertension, hearing loss, fatigue, loss of appetite, anorexia, peculiar smell, dark urine, light stools, steatorrhea, failure to thrive, and renal failure. 
     
     
         42 . The method of  claim 31 , wherein the pediatric patient is between 6 months to 12 years old. 
     
     
         43 . The method of  claim 31 , wherein less than 10% of the ASBTI is systemically absorbed. 
     
     
         44 . The method of  claim 33 , wherein the composition further comprises a bile acid sequestrant or binder. 
     
     
         45 . The method of  claim 31 , wherein the ASBTI is effective for decreasing serum and/or hepatic bile acid levels in the pediatric subject as compared to bile acid levels prior to administration of the ASBTI. 
     
     
         46 . The method of  claim 31 , wherein the ASBTI is effective for decreasing at least 20% of serum and/or hepatic bile acid levels in the pediatric subject as compared to bile acid levels prior to administration of the ASBTI. 
     
     
         47 . The method of  claim 31 , wherein the ASBTI is effective for decreasing at least 30% of serum and/or hepatic bile acid levels in the pediatric subject as compared to bile acid levels prior to administration of the ASBTI. 
     
     
         48 . The method of  claim 31 , wherein the ASBTI is effective for decreasing at least 40% of serum and/or hepatic bile acid levels in the pediatric subject as compared to bile acid levels prior to administration of the ASBTI. 
     
     
         49 . The method of  claim 31 , wherein the ASBTI is effective for decreasing at least 50% of serum and/or hepatic bile acid levels in the pediatric subject as compared to bile acid levels prior to administration of the ASBTI.